634 related articles for article (PubMed ID: 32062795)
1. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
[TBL] [Abstract][Full Text] [Related]
2. Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y
Panzer B; Wadowski PP; Huber K; Panzer S; Gremmel T
Diabet Med; 2022 Aug; 39(8):e14868. PubMed ID: 35514270
[TBL] [Abstract][Full Text] [Related]
3. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
[TBL] [Abstract][Full Text] [Related]
4. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Wagner H; Lood C; Borna C; Gidlöf O; Truedsson L; Brown P; Zhou C; Winters K; Jakubowski JA; Erlinge D
J Thromb Thrombolysis; 2016 Oct; 42(3):369-75. PubMed ID: 27165280
[TBL] [Abstract][Full Text] [Related]
7. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
8. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z; Zhou DY; Su Y; Si LY; Xu Q
BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
11. Circulating MicroRNAs and Monocyte-Platelet Aggregate Formation in Acute Coronary Syndrome.
Stojkovic S; Wadowski PP; Haider P; Weikert C; Pultar J; Lee S; Eichelberger B; Hengstenberg C; Wojta J; Panzer S; Demyanets S; Gremmel T
Thromb Haemost; 2021 Jul; 121(7):913-922. PubMed ID: 33469902
[TBL] [Abstract][Full Text] [Related]
12. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
[TBL] [Abstract][Full Text] [Related]
13. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
[TBL] [Abstract][Full Text] [Related]
14. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
15. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y
Chyrchel B; Drożdż A; Długosz D; Stępień EŁ; Surdacki A
Int J Med Sci; 2019; 16(2):264-275. PubMed ID: 30745807
[No Abstract] [Full Text] [Related]
16. Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome.
Ilardi F; Gargiulo G; Paolillo R; Ferrone M; Cimino S; Giugliano G; Schiattarella GG; Verde N; Stabile E; Perrino C; Cirillo P; Coscioni E; Morisco C; Esposito G
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):660-666. PubMed ID: 32520854
[TBL] [Abstract][Full Text] [Related]
17. Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction.
Beigel R; Mazin I; Koifman E; Shechter M; Pres H; Shlomo N; Rosenberg N; Asher E; Matetzky S
J Thromb Haemost; 2018 Apr; 16(4):663-669. PubMed ID: 29443445
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors.
Wadowski PP; Pultar J; Weikert C; Eichelberger B; Lang IM; Koppensteiner R; Panzer S; Gremmel T
J Cardiovasc Pharmacol Ther; 2021 May; 26(3):260-268. PubMed ID: 33107322
[TBL] [Abstract][Full Text] [Related]
19. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
[TBL] [Abstract][Full Text] [Related]
20. A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.
Lee JH; Ahn SG; Park B; Park SW; Kang YS; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J
Korean J Intern Med; 2015 Sep; 30(5):620-8. PubMed ID: 26354056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]